Objective: Cervical dystonia (CD) lacks an objective quantitative measure. Electrical impedance myography (EIM) is a non-invasive assessment method sensitive to changes in muscle structure and physiology. We evaluate the potential role of EIM in quantifying CD, hypothesizing that patients would demonstrate differences in the symmetry of muscle electrical resistance compared to controls, and that this asymmetry would decrease after botulinum neurotoxin (BoNT) treatment. Methods: EIM was performed on the sternocleidomastoid (SCM) and cervical paraspinal (PS) muscles of CD patients and age-matched controls. 50 kHz resistance was analyzed, comparing side-to-side asymmetry in patients and controls, and, in patients, before and after BoNT treatment. Results: Sixteen patients and 10 controls were included. Resistance asymmetry was on average 3-5 times higher in patients than controls. Receiver operating characteristic analysis demonstrated 91% accuracy of discriminating CD from normal. From pre-treatment to maximum BoNT effect, asymmetry decreased from 20.8(13.9-26.1)% to 6.2(3.1-9.9)% (SCM), and from 16.0(14.3-16.0)% to 8.4(7.0-9.2)% (PS), p < 0.05 (median, interquartile range). Conclusions: EIM effectively differentiates normal subjects from CD patients by revealing asymmetries in resistance values and detects improvement in muscle symmetry after treatment. Significance: These results suggest that EIM, a painless, non-invasive measure, can provide a useful quantitative metric in CD evaluation and deserves further study.
Introduction
Cervical dystonia (CD) is the most common focal dystonia (Stacy, 2008) . Prevalence estimates vary from 5.7/100000 (ESDE Collaborative Group, 2000) to 0.4% of the population (Jankovic et al., 2007) . Widespread abnormal excitability in the brainstem, basal ganglia and cortical circuits is associated with CD (Tolosa and Marti, 2004; Singer and Velickovic, 2008) . At muscular level, the end result is abnormal activation, with prominent EMG bursts and co-contraction of agonists and antagonists (Deuschl et al., 1992) . This abnormal activation is almost always asymmetric side-toside, resulting in prominent asymmetric head/neck/shoulder position and muscle hypertrophy. Muscle activation on EMG can be used to guide botulinum neurotoxin (BoNT) injections and to identify the most affected muscles, but not routinely for quantifying dystonia or its response to treatment.
The most effective therapy for CD remains BoNT injections (Simpson et al., 2008) . Deep brain stimulation (DBS) therapy is another valid option for intractable CD, with less predictable effects (Ostrem and Starr, 2008; Pretto et al., 2008) . Since effective therapies are available, objective measures are very important but generally lacking for CD monitoring and could play a role in more effectively tailoring therapy in a given patient or in clinical trials. To date, dystonia evaluation has been performed semi-quantitatively on a clinical basis, using rating scales. The Burke-FahnMarsden (BFM) scale (Burke et al., 1985) has been utilized in clinical and research contexts since the 1980s, and the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) (Consky et al., 1990; Comella et al., 1997 ) is designed specifically for CD.
Electrical impedance myography (EIM) is a relatively new, noninvasive technology that to date is primarily being studied in the evaluation of neuromuscular diseases, including myositis and amyotrophic lateral sclerosis (Tarulli et al., 2005; Rutkove et al., 2005 Rutkove et al., , 2007 . It is based on the application of low-intensity, highfrequency electrical current to localized areas of muscle using surface electrodes and measuring the resulting electrical voltages from which an impedance can be calculated (Rutkove et al. 
